Загрузка...
CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
BACKGROUND: CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic...
Сохранить в:
| Опубликовано в: : | Brain Behav |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6379644/ https://ncbi.nlm.nih.gov/pubmed/30656853 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/brb3.1215 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|